Eli Lilly’s Next-gen $6.5B API and GLP-1 Orforglipron Facility, Houston, Texas, USA
Eli Lilly and Company has announced plans to build a $6.5 billion next-generation active pharmaceutical ingredient (API) manufacturing facility at
Read moreEli Lilly and Company has announced plans to build a $6.5 billion next-generation active pharmaceutical ingredient (API) manufacturing facility at
Read moreLexicon Pharmaceuticals announced an exclusive worldwide licensing agreement with Novo Nordisk for LX9851, a first-in-class oral non-incretin therapy in development for
Read moreAmerican multinational pharma company Incyte and AI-focused biotech Genesis Therapeutics have announced a strategic collaboration to leverage artificial intelligence for
Read moreDarmstadt headquartered Merck KGaA, a leading science and technology company operating in the U.S. & Canada as MilliporeSigma, has announced a
Read moreLonza is building an Ibex™ Solutions campus of five state-of-the-art manufacturing complexes that deliver biopharmaceutical customers agile capability at every stage
Read more